Buffer-free high pH mobile phase LC-MS/MS for determination of the alcohol biomarker phosphatidylethanol 16:0/18:1 and 20 drugs and metabolites in whole blood

Article

作者: Maria, Marisa H ; Jørgenrud, Benedicte ; Berg, Thomas ; Nilsson, Galina ; Maria, Marisa H. ; McQuade, Tao

BACKGROUND:

Acidic mobile phases are commonly used in reversed phase liquid chromatography tandem mass spectrometry (LC-MS/MS) bioanalysis. However, increased sensitivity, improved peak symmetry, and increased retention, especially for basic hydrophilic drugs have been observed using basic mobile phases. In our previous acidic mobile phase LC-MS/MS method we needed two injections (0.4 and 2.0 μL) of each sample for this task, which is inefficient. The aim of this study was to investigate if basic mobile phase LC-MS/MS could be used to determine phosphatidylethanol 16:0/18:1 and 20 other drugs and metabolites with satisfactory sensitivity in one single run.

METHODS:

Whole blood was prepared by 96-well supported-liquid extraction using heptane/ethyl acetate/2-propanol (16:64:20, v:v:v). Chromatographic separation was achieved on an Acquity BEH C₁₈ column (50 × 2.1 mm I.D.), using a mobile phase with 0.025 % ammonia, pH 10.7 (Solvent A) and methanol (Solvent B). All compounds had isotope-labelled internal standards.

RESULTS:

The method was fully validated. Recovery was between 63 and 91 % for 20 compounds and 10 % for benzoylecgonine. Matrix effects were low, except for ion enhancement of buprenorphine and ion suppression for THC. However, internal standards compensated for these effects. Inter-assay precision and accuracy were < ± 20 % for all compounds at five tested concentrations, except for methamphetamine at the highest concentration.

CONCLUSION:

An LC-MS/MS method for simultaneous determination of PEth 16:0/18:1 and 20 drugs and metabolites in whole blood were for the first time developed and validated. Retention of PEth 16:0/18:1 was, in contrast to the other 20 compounds, largely affected by mobile phase buffer concentration. The buffer free basic mobile phase ensured that phosphatidylethanol 16:0/18:1 eluted before most of the unwanted phospholipids.

2025-01-01·BIOSENSORS & BIOELECTRONICS

NanoMIP beacons with a co-operative binding mechanism for the all-in-one detection of methamphetamine aptamer complexes

Article

作者: Ashley, Jon ; Sun, Yi ; Goulding, William

Methamphetamine is a highly addictive stimulant with significant public health implications, necessitating the development of rapid, sensitive, and reliable detection methods. Traditional analytical techniques, though accurate, often involve complex sample preparation, expensive equipment, and lengthy analysis times. This study presents the design, synthesis, and application of nanoMIP beacons with a unique co-operative binding mechanism for the detection of methamphetamine. NanoMIP beacons selective for methamphetamine/aptamer complexes were synthesized using a solid-phase synthesis method that involved the bio-conjugation of an aptamer on the stationary phase and the incubation of methamphetamine to form a methamphetamine-aptamer complex. The resultant nanoMIP beacons were eluted off the affinity column and characterised using transmission electron microscopy. The co-operative binding mechanism, which relies on the structure-switching capability of the aptamer upon analyte binding was demonstrated through comparison of the fluorescence quenching signal of a scrambled sequence and nanoNIP controls. The fluorescence quenching assay was established using a fixed optimal concentration of aptamer and varying amounts of methamphetamine. The nanoMIP beacons showed enhanced the sensitivity (LOD = 23 ± 3.5 nM) and excellent selectivity, with a 40-fold increase in quenching for methamphetamine compared to other illicit drugs. The nanoMIP beacons demonstrated acceptable sample recoveries in both urine diluent and 50% human serum. This work provides a new strategy for the development of hybrid nanoMIP/aptamer-based sensors and provides a robust analytical tool for combating methamphetamine abuse.

2025-01-01·TALANTA

Towards the development of a portable device based on modified-voltammetric sensors for the detection of illicit drugs and seized samples

Article

作者: Sánchez-Pereña, Ángela ; Truță, Florina Maria ; Cristea, Cecilia ; Cetó, Xavier ; Comellas-Tena, Sara ; Truta, Florina Maria ; del Valle, Manel ; Drăgan, Ana-Maria ; Del Valle, Manel ; Dragan, Ana-Maria ; Tertiș, Mihaela ; Rodríguez-Franch, Elena ; Tertis, Mihaela

Illicit drugs are a global burden, not only for society, but also for the various control authorities for which its rapid on-site detection remains a challenge. In this context, the potential of a voltammetric electronic tongue (ET) for the analysis of different drugs is evaluated herein. Concretely, the discrimination and identification of cocaine, heroin, 3,4-Methylenedioxymethamphetamine (MDMA), methamphetamine and ketamine in self-prepared and real samples were attempted. For its analysis, an array of three carbon-based screen-printed electrodes (SPE) was prepared, and their responses towards the different drugs and some of the more common cutting agents and adulterants were assessed by means of square wave voltammetry (SWV). To this aim, a tiny amount (ca. 3 mg) of the drug powder was added to the electrochemical cell containing phosphate buffer (pH 12), shaken, and measured directly without any other pre-treatment than its dilution. Next, to identify their characteristic fingerprint, obtained voltammograms were submitted to linear discriminant analysis (LDA), which allowed to correctly identify the different drugs regardless of the presence of the different cutting agents and other possible interfering compounds, or their concentration. Satisfactory results were obtained both for the synthetic and the "street" seized samples, with a classification rate of 100 % for the external test subset of the latter (n = 10).

104

项与甲基安非他明相关的新闻（医药）

2024-10-31

·GlobeNewswire-Health Care

Intelligent Bio Solutions Partners with B2i Digital to Amplify Investor Outreach

Digital Marketing Initiatives to Highlight Innovative Non-Invasive Drug Screening Technology and Market Expansion PlansNEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a strategic partnership with B2i Digital to launch an investor-focused marketing campaign. B2i Digital will employ advanced digital marketing strategies to raise awareness of INBS’ patented drug screening technology, which offers a fast, non-invasive, and efficient alternative to traditional drug tests. “Intelligent Bio Solutions has developed a groundbreaking system that addresses a critical need in industries requiring quick and reliable drug screening,” said David Shapiro, CEO of B2i Digital. “The company’s Intelligent Fingerprinting Drug Screening System, expected to enter the U.S. market next year following the company’s FDA 510(k) submission and anticipated clearance, provides substantial advantages over traditional methods and offers significant growth potential. We are proud to raise awareness of a company whose products address a critical need across industries worldwide.” B2i Digital will leverage data-driven targeting across digital channels to reach investors with a focus on healthcare technology and market innovation. The partnership will emphasize Intelligent Bio Solutions’ unique technology, growing revenue, and planned US product launch in 2025. “As we plan for our entry into the US market, enhancing our communications and outreach to the investment community is crucial,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “Our partnership with B2i Digital allows us to connect with investors who see the potential in our unique approach to drug screening, particularly in industries where workplace safety is paramount.” About B2i Digital, Inc. B2i Digital, Inc. leverages the latest digital marketing technologies to tell a company’s story to retail investors, institutional investors, and research analysts. B2i Digital creates robust profiles for companies on its platform, b2idigital.com, and launches targeted digital marketing campaigns to bring the most relevant investors to each company based on its sector, stage in its capital markets evolution, and overall company story. The company was founded in 2021 by David Shapiro, previously the Chief Marketing Officer for Maxim Group LLC and its investor awareness platform, M-Vest.com. B2i Digital Contact Information: David ShapiroChief Executive Officer B2i Digital, Inc. https://b2idigital.com212.579.4844 Officedavid@b2idigital.com https://www.linkedin.com/in/davidshapironychttps://www.linkedin.com/company/b2i-digitalhttps://x.com/b2idigitalhttps://www.facebook.com/b2idigitalhttps://www.instagram.com/b2i_digitalhttps://www.youtube.com/@b2idigitalhttps://www.pinterest.com/b2idigital/https://www.tiktok.com/@b2idigitalhttps://www.threads.net/@b2i_digital About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. For more information, visit: http://www.ibs.inc/ Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Intelligent Bio Solutions Company Contact:   Intelligent Bio Solutions Inc.  info@ibs.inc   LinkedIn | Twitter  Intelligent Bio Solutions Investor & Media Contact:  Valter Pinto, Managing Director  KCSA Strategic Communications  PH: (212) 896-1254  INBS@kcsa.com

2024-10-24

·BioSpace

New Study Reveals Unprecedented Increases in Fentanyl and Stimulant Concentrations in Urine Drug Test Results

SAN DIEGO--(BUSINESS WIRE)--A study published in JAMA Network Open , led by Andrew Huhn, PhD, MBA, Associate Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine, Kelly Dunn, PhD, MBA, Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine, and co-authored by Millennium Health researchers, illustrates striking increases in the amounts of illicit fentanyl, methamphetamine, and cocaine detected in urine drug testing (UDT) specimens since 2013. The analysis showed that the concentrations of fentanyl and methamphetamine were 8.3 and 5.2 times higher, respectively, in 2023 compared to 2013 (Figure). Cocaine concentrations also doubled across this time period, whereas those for heroin fell by more than half. The JAMA Network Open article can be accessed here . “Fentanyl, methamphetamine, and cocaine concentrations are higher now relative to any time in the past decade, suggesting that the people who are using these drugs are doing so in larger quantities and/or with greater frequency now,” said Huhn. “The findings also demonstrate that aggregated, quantitative UDT data offer a scalable surveillance method that can provide swift and nimble feedback on real-time changes in drug exposure levels as well as emerging threats, like xylazine, that are not routinely captured by other methods,” he added. The analysis of 921,931 unique patient UDT specimens collected in substance use disorder treatment settings across the U.S. also evaluated how these concentrations have changed in different parts of the country. With a few exceptions (e.g., greater methamphetamine concentrations in the West and part of the South, largely stable heroin concentrations in the West), changes in drug exposure concentrations have been relatively similar across the U.S. over time. “These findings reveal that the drug use epidemic is evolving not only in terms of what drugs are being used but how much drug is being used ,” said Millennium Health Chief Clinical Officer Angela Huskey, PharmD, CPE. “This is the most granular assessment of drug use patterns in the U.S. to date and highlights an important, underappreciated nuance about drug use that may affect overdose risk and other clinically relevant phenomena.” About Millennium Health Millennium Health is an accredited specialty laboratory with over 15 years of experience in drug testing . We provide objective information about patients’ recent use of prescription medications and/or illicit drugs which helps clinicians monitor and treat millions of Americans living with chronic pain, substance use disorders, mental health disorders or other health conditions. Our ability to monitor drug use trends allows us to alert clinicians, health agencies and others to real-time drug use changes to help inform more targeted drug overdose prevention and response strategies to save lives. Contacts MEDIA CONTACT: Jody Schneider Millennium Health Jody.Schneider@millenniumhealth.com 619-917-6810

临床研究

2024-09-27

·GlobeNewswire-Health Care

Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of in-clinic testing proposed to the FDA earlier this year in the Company’s clinical study plan. The clinical studies are a key element of the Company's 510(k) submission, designed to demonstrate the accuracy and reliability of its sweat-based testing method. The studies included a pharmacokinetic (PK) study, which aimed to demonstrate that the measurement of drugs in fingerprint sweat delivers results comparable or superior to other specimen matrices, such as blood, saliva and urine. In addition to the PK study, a method comparison and usability study was conducted to validate the accuracy of the Company's fingerprint sweat drug screening method in the hands of intended users. The clinical phase of the PK study concluded in June 2024, with all laboratory analyses completed and data currently under review. The method comparison and usability studies, carried out across three sites, involved 135 subjects who were randomly dosed with codeine and then tested using the Company's drug screening system. The accuracy of the screening system results will be assessed relative to a traceable, laboratory-based reference method. “Executing these clinical studies required diligence and collaboration across multiple functions within Intelligent Bio Solutions and our CRO partners, CenExel and Cliantha,” said Daniel Brown, Head of Clinical Affairs at INBS. “Completion of these in-clinic studies marks a significant achievement for our team and brings us closer to our goal of obtaining FDA 510(k) Notification clearance,” said Harry Simeonidis, President and CEO at INBS. “The early feedback on results from these studies demonstrates the potential of our fingerprint-based testing method to provide a non-invasive, reliable alternative to traditional drug testing methods and address the needs of diverse sectors, including workplaces and government agencies.” With the in-clinic testing phase now complete, INBS is preparing for the next steps in its FDA submission process. Achieving FDA clearance will enable the Company to market its product as a clinically validated tool, paving the way for adoption in the US and potentially transforming the landscape of drug screening. The Company expects clinical data analysis to be completed in the fourth calendar quarter of 2024 and to submit the 510(k) package during the same quarter. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. For more information, visit: http://www.ibs.inc/ Forward-Looking Statements: Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact: Intelligent Bio Solutions Inc.info@ibs.incLinkedIn | Twitter Investor & Media Contact: Valter Pinto, Managing DirectorKCSA Strategic CommunicationsPH: (212) 896-1254INBS@kcsa.com

临床研究

100 项与甲基安非他明相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08187	甲基安非他明	N06BA03	DB01577

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑损伤	临床1期	美国	Sinapis Pharma, Inc.	-
脑损伤	临床1期	-	The University of Montana	-
脑损伤	临床1期	-	Sinapis Group	-
脑卒中	临床1期	美国	Sinapis Pharma, Inc.	-
脑卒中	临床1期	-	The University of Montana	-
脑卒中	临床1期	-	Sinapis Group	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03790618 (ESP, CTgov)	临床1期	-	36	3,4-Methylenedioxymethamphetamine+methamphetamine (Placebo)	鏇艱壓窪顧構選蓋鹽壓(鑰鹹築夢築網構襯遞齋) = 簾鑰繭餘鹹鏇願鏇築製糧鑰壓壓艱築顧憲夢範 (選蓋鹹製餘齋構願艱艱, 鹹觸鹹憲觸壓製網範艱 ~ 願鹽鏇壓簾蓋構獵獵範) 更多	-	2024-01-05
				3,4-Methylenedioxymethamphetamine+methamphetamine (Low Dose MDMA)	鏇艱壓窪顧構選蓋鹽壓(鑰鹹築夢築網構襯遞齋) = 製範艱網鹹鏇鑰願壓積糧鑰壓壓艱築顧憲夢範 (選蓋鹹製餘齋構願艱艱, 憲蓋願鹹網構夢衊鏇餘 ~ 遞鑰廠選鹽顧鬱鏇淵築) 更多
NCT04178993 (CTgov)	临床1期	甲基苯丙胺依赖	8	Placebo oral capsule+Methylphenidate+Methamphetamine (Placebo Comparator: Placebo)	鏇範選遞積願築繭蓋製(廠遞獵齋鹹淵顧夢鏇積) = 鹽鬱膚鹽鑰淵蓋積構憲構壓廠淵繭顧膚製鹹顧 (獵鑰獵醖廠衊鹹顧糧夢, 齋醖壓簾糧糧淵膚鹹糧 ~ 膚獵築襯廠獵淵鏇築淵) 更多	-	2023-01-09
				Placebo oral capsule+Methylphenidate+Duloxetine+Methamphetamine (Active Comparator: Duloxetine)	廠衊選網鏇鹽膚蓋廠糧(繭製糧鬱窪獵襯鏇艱艱) = 選蓋鑰憲衊膚簾築襯範鹹網壓齋廠醖製製艱衊 (憲醖餘壓餘鬱蓋獵簾鹽, 艱獵壓選觸憲鹽鹹醖鑰 ~ 製遞夢淵構艱襯遞鑰夢) 更多
ESC2019	N/A	扩张型心肌病	-	methamphetamine	製築製積遞顧遞襯遞顧(鬱網醖積繭鬱築遞廠窪) = 獵製衊網網齋遞夢繭襯憲顧觸鬱積鬱製獵襯遞 (淵觸願製壓醖衊簾淵願 ) 更多	-	2019-09-02
ISC2019	N/A	脑出血	596	Patients with UDS for methamphetamines	鹹獵憲餘鹽齋鏇遞願選(憲淵夢鏇夢夢夢鏇鬱鬱) = 製衊簾襯觸鑰蓋憲壓醖鑰網衊選餘鹹繭鑰襯範 (鹹鹹網構獵鹽積醖繭獵 )	-	2019-02-01
				Patients without UDS for methamphetamines	鹹獵憲餘鹽齋鏇遞願選(憲淵夢鏇夢夢夢鏇鬱鬱) = 壓願鹹鹹網繭鬱廠製蓋鑰網衊選餘鹹繭鑰襯範 (鹹鹹網構獵鹽積醖繭獵 )
NCT02323048 (CAM, CTgov)	N/A	物质滥用	90	placebo+methamphetamine (Paired, Low Reward)	獵糧鏇淵願鏇窪鹽鹽夢(構築選鬱齋衊鬱願窪簾) = 壓鏇鹹淵築顧齋餘遞膚鏇鹽簾膚製襯憲糧網鏇 (蓋構繭鹹繭蓋顧獵醖鏇, 築膚艱遞願淵鹽簾顧鏇 ~ 鹽窪襯鑰積遞壓衊顧壓) 更多	-	2018-07-26
				placebo+methamphetamine (Paired, High Reward)	獵糧鏇淵願鏇窪鹽鹽夢(構築選鬱齋衊鬱願窪簾) = 獵餘醖觸鑰襯蓋憲構觸鏇鹽簾膚製襯憲糧網鏇 (蓋構繭鹹繭蓋顧獵醖鏇, 鏇選糧窪觸觸觸鏇鏇夢 ~ 鹹衊鏇製壓網鏇餘廠築) 更多
MDS2017	N/A	-	-	Methamphetamine users (males)	窪積糧憲齋構醖夢鏇獵(鏇餘齋艱鏇選齋網鹽襯) = 餘壓淵範糧製衊獵淵網衊觸鑰襯餘鏇壓壓壓鹽 (夢艱膚獵構鏇選艱積窪 )	-	2017-06-04
				Methamphetamine users (females)	窪積糧憲齋構醖夢鏇獵(鏇餘齋艱鏇選齋網鹽襯) = 鑰鹹範獵獵鹽憲鹹積艱衊觸鑰襯餘鏇壓壓壓鹽 (夢艱膚獵構鏇選艱積窪 )
AAN2017	N/A	脑出血 methamphetamine positive toxicology screen	-	methamphetamine	製衊鹽糧夢鹹築顧願鬱(繭壓築壓製廠鑰鑰夢繭) = 積齋簾糧膚網範願構齋醖積壓構衊艱獵觸鬱簾 (選衊獵鏇鏇構艱顧範衊 )	积极	2017-04-18